Swiss pharmaceuticals producer Roche Holding AG said Nov. 15 it has received approval from the U.S. regulators for its anemia drug Mircera, but is still awaiting resolution of a patent case before launching the drug in the United States. Mircera, which has been approved by the U.S. Food and Drug Administration for patients with anemia caused by kidney failure, is the subject of a legal tussle between Roche and rival Amgen Inc.
November 16, 2007 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Swiss pharmaceuticals producer Roche Holding AG said Nov. 15 it has received approval from the U.S. regulators for its anemia drug Mircera, but is still awaiting resolution of a patent case before launching the drug in the United States.
Mircera, which has been approved by the U.S. Food and Drug Administration for patients with anemia caused by kidney failure, is the subject of a legal tussle between Roche and rival Amgen Inc.
Presented by BigVoodoo
The premier educational and networking event for employee benefits brokers and agents.
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Shipman is seeking an associate to join our Labor & Employment practice in our Hartford, New Haven, or Stamford office. Candidates shou...
Evergreen Trading is a media investment firm headquartered in NYC. We help brands achieve their goals by leveraging their unwanted assets to...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
